期刊
NETHERLANDS HEART JOURNAL
卷 25, 期 4, 页码 231-242出版社
BOHN STAFLEU VAN LOGHUM BV
DOI: 10.1007/s12471-017-0959-2
关键词
Atherosclerosis; Hypercholesterolaemia; Low-density lipoprotein; Cardiovascular disease; Statins; Proprotein convertase subtilisin/kexin type-9
资金
- Amgen
- Astra-Zeneca
- Lilly
- Merck-Schering-Plough
- Pfizer
- Sanofi Aventis
- The Medicine Company
- Netherlands Heart Foundation
- CardioVascular Research the Netherlands (CVON)
- Interuniversity Cardiology Institute of the Netherlands
- European Community Framework KP7 Programme
Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications. In this review, we first provide a background consisting of the current understanding of the pathophysiology and treatment of atherosclerotic disease, followed by our future perspectives on several novel classes of drugs that target atherosclerosis. The focus of this update is on the pathophysiology and medical interventions of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a) (Lp(a)).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据